Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Innoviva (NASDAQ:INVA) is the #1 top biotech stock out of 617 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Innoviva (NASDAQ:INVA) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Innoviva (NASDAQ:INVA) has a Due Diligence Score of 45, which is 22 points higher than the biotech industry average of 23.

INVA passed 14 out of 33 due diligence checks and has strong fundamentals. Innoviva has seen its stock return 9.34% over the past year, overperforming other biotech stocks by 52 percentage points.

Innoviva has an average 1 year price target of $32.00, an upside of 58.89% from Innoviva's current stock price of $20.14.

Innoviva stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Innoviva, 25% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 25% have issued a Strong Sell.

Beone Medicines (NASDAQ:ONC) is the #2 top biotech stock out of 617 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Beone Medicines (NASDAQ:ONC) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: C, and AI: B.

Beone Medicines (NASDAQ:ONC) has a Due Diligence Score of 53, which is 30 points higher than the biotech industry average of 23.

ONC passed 18 out of 33 due diligence checks and has strong fundamentals. Beone Medicines has seen its stock return 76.19% over the past year, overperforming other biotech stocks by 119 percentage points.

Beone Medicines has an average 1 year price target of $390.88, an upside of 25.82% from Beone Medicines's current stock price of $310.67.

Beone Medicines stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Beone Medicines, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Biocryst Pharmaceuticals (NASDAQ:BCRX) is the #3 top biotech stock out of 617 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Biocryst Pharmaceuticals (NASDAQ:BCRX) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: B.

Biocryst Pharmaceuticals (NASDAQ:BCRX) has a Due Diligence Score of 17, which is -6 points lower than the biotech industry average of 23. Although this number is below the industry average, our proven quant model rates BCRX as a "A".

BCRX passed 6 out of 33 due diligence checks and has weak fundamentals. Biocryst Pharmaceuticals has seen its stock return 1.74% over the past year, overperforming other biotech stocks by 44 percentage points.

Biocryst Pharmaceuticals has an average 1 year price target of $20.67, an upside of 172.29% from Biocryst Pharmaceuticals's current stock price of $7.59.

Biocryst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Biocryst Pharmaceuticals, 33.33% have issued a Strong Buy rating, 55.56% have issued a Buy, 11.11% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 12.5%, which is 10 percentage points higher than the biotech industry average of 3%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 2.28%, which is -1 percentage points lower than the biotech industry average of 3%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 49.4% indicates that its dividend yield is sustainable for the long-term.

Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.55%, which is -2 percentage points lower than the biotech industry average of 3%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has not shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 64% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were down -0.98% in the last day, and down -1.24% over the last week. Sonnet Biotherapeutics Holdings was the among the top losers in the biotechnology industry, dropping -59.35% yesterday.

Sonnet BioTherapeutics Holdings shares are trading lower after the company announced its stockholders approved a business combination with Hyperliquid Strategies and Rorschach I.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 17.73% in the past year. It has overperformed other stocks in the biotech industry by 60 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 94% in the past year. It has overperformed other stocks in the biotech industry by 137 percentage points.

Innoviva (NASDAQ:INVA) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Innoviva has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Innoviva's stock has gained 9.34% in the past year. It has overperformed other stocks in the biotech industry by 52 percentage points.

60.26% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 49.75% over the next year.

3.73% of biotech stocks have a Zen Rating of A (Strong Buy), 6.21% of biotech stocks are rated B (Buy), 45.13% are rated C (Hold), 32.51% are rated D (Sell), and 12.42% are rated F (Strong Sell).